

01/08/2025

Variation of Service Level Agreement (SLA) for Supervised Consumption.

Letter to confirm no changes to the Service Level Agreements (SLA) for Supervised Consumption.

Forward Leeds

Dear Community Pharmacy Contractor,

Please accept this letter of communication as an update for the Service Level Agreement (SLA) which is in place between Waythrough and Pharmacy Contractors to deliver Supervised Consumption.

The current SLA (Service Level Agreement for Pharmacy Supervised Consumption V10.0) will have the following changes in line with discussions between the service, local commissioners and Community Pharmacy West Yorkshire:

- 2.3 *The LPC, Community Pharmacy West Yorkshire will act as an agent between Waythrough and the Pharmacy for processing claims for payment via PharmOutcomes as outlined in the local PharmOutcomes licence agreement.*
- 2.4 *The agreed fee to be paid per supervised dose ('per swallow') is as follows:*
- *Methadone liquid (all brands) and Espranor® oral lyophilisate: £1.60*
 - *Buprenorphine sub-lingual tablet (all brands): £3.35*

(previously: Methadone liquid (all brands): £1.60 Espranor® oral lyophilisate: £1.60, Buprenorphine sub-lingual tablet (all brands): £3.25)

Please sign the section below to confirm receipt of this variation in SLA letter to confirm no changes to the SLA and return to contracts@waythrough.org.uk. If we do not receive this letter within 30 days we will presume acceptance of the terms within this letter.

Many thanks,
Barbara Zub
National Pharmacy Technician

I confirm receipt and acceptance of the details outlined in this letter concerning the Supervised Consumption and/or Needle and Syringe Programme.

Name:

Role:

Pharmacy Name:

Pharmacy Address:

Date: